Table 2.
Univariable and multivariable analyses of variables potentially associated with isavuconazole dose-normalised trough concentration
| Characteristics | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| β coefficient | p value | β coefficient | p value | |
| Clinical features | ||||
| Sex, M/F | 0.2866 | 0.126 | ||
| Age (y) | 0.0007 | 0.897 | ||
| Underlying liver disease | − 0.1038 | 0.731 | ||
| Haematology unit | 0.4897 | 0.007 | ||
| Biological parameters before isavuconazole initiation | ||||
| Total proteins (g/L) (n = 101) | 0.0116 | 0.164 | ||
| Albumin (g/L) (n = 77) | 0.0463 | 0.001 | ||
| AST (U/L) (n = 99) | − 0.0003 | 0.486 | ||
| ALT (U/L) (n = 99) | − 0.0001 | 0.584 | ||
| GGT (U/L) (n = 99) | 0.0003 | 0.417 | ||
| ALP (U/L) (n = 99) | 0.0002 | 0.698 | ||
| Total bilirubin (µmol/L) (n = 99) | 0.0001 | 0.981 | ||
| Biological parameters on the day of TDM | ||||
| Total proteins (g/L) (n = 94) | 0.0199 | 0.028 | ||
| Albumin (g/L) (n = 74) | 0.0424 | 0.001 | 0.0339 | 0.009 |
| AST (U/L) (n = 100) | − 0.0001 | 0.536 | ||
| ALT (U/L) (n = 100) | − 0.0003 | 0.494 | ||
| GGT (U/L) (n = 100) | 0.000001 | 0.997 | ||
| ALP (U/L) (n = 99) | − 0.0001 | 0.859 | ||
| Total bilirubin (µmol/L) (n = 91) | − 0.0002 | 0.961 | ||
| Treatments | ||||
| Oral route | 0.4828 | 0.015 | 0.0536 | 0.792 |
| Isavuconazole duration (day) (n = 81) | 0.0013 | 0.058 | ||
| Time to TDM from isavuconazole initiation (day) | 0.0021 | 0.003 | 0.0014 | 0.212 |
| Previous exposure to azoles (< 6 months) | 0.2229 | 0.217 | ||
| Hepatotoxic co-medication | − 0.0310 | 0.866 | ||
| Liver safety (n = 99) | ||||
| Abnormal liver test during treatment | − 0.0261 | 0.928 | ||
| Isavuconazole discontinuation | 0.2730 | 0.379 | ||
| Isavuconazole induced liver injury | 0.2730 | 0.379 | ||
ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyl transferase, TDM therapeutic drug monitoring